Enrollment open • Phase classification • Trial initiation date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • FGFR (Fibroblast Growth Factor Receptor) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 expression • CTLA4 expression
|
gemcitabine • albumin-bound paclitaxel • erfonrilimab (KN046) • Sulanda (surufatinib)